Vetr Upgrades Valeant After Price Dips

0 Comments 1 view(s)

The Vetr crowd on Thursday upgraded its rating on Valeant Pharmaceuticals International, Inc. (NYSE: VRX), from 4 stars (Buy), issued two days ago, to 5 stars.

Latest Ratings for VRX

Date Firm Action From To
Nov 2017 Deutsche Bank Maintains Hold
Nov 2017 BMO Capital Maintains Market Perform
Jul 2017 Deutsche Bank Maintains Hold

View More Analyst Ratings for VRX

View the Latest Analyst Ratings

read more